2022
Current status of clinical outcome measures in inclusion body myositis: a systematised review.
Roy B, Lucchini M, Lilleker J, Goyal N, Naddaf E, Adler B, Alfano L, Malandraki G, Focht Garand K, Mochel D, Badrising U, Machado P, Pagkatipunan R, Ramdharry G, Wang L, Funaro M, Schmidt J, Kushlaf H, Schiopu E, Stipancic K, Goyal N, d'Alessandro M, Conticini E, Cruz-Coble B, Lloyd T. Current status of clinical outcome measures in inclusion body myositis: a systematised review. Clinical And Experimental Rheumatology 2022, 41: 370-378. PMID: 36762744, DOI: 10.55563/clinexprheumatol/ifacv3.Peer-Reviewed Original ResearchConceptsIBM functional rating scaleInclusion body myositisIdiopathic inflammatory myopathiesOutcome measuresClinical studiesBody myositisMuscle testingClinical trialsMaximal voluntary isometric contraction testingOpen-label clinical trialSix-minute walk distanceSporadic inclusion body myositisQuantitative muscle testingSecondary outcome measuresManual muscle testingPrimary outcome measureClinical outcome measuresCore set measuresNew potential therapeuticsSuitable outcome measuresThigh muscle volumeDifferent outcome measuresInflammatory myopathiesWalk distancePharmacological therapy
2021
A systematic review of ketamine for the treatment of depression among older adults
Farheen S, Gupta A, Dhar R, Patadia P, Funaro M, Bhattacharya G, Tampi R. A systematic review of ketamine for the treatment of depression among older adults. American Journal Of Geriatric Psychiatry 2021, 29: s93-s96. DOI: 10.1016/j.jagp.2021.01.089.Peer-Reviewed Educational MaterialsPrimary outcome measureUse of ketamineLate-life depressionTreatment of depressionOlder adultsElectroconvulsive therapyReceptor antagonistLife depressionOutcome measuresCurrent evidenceDepressive symptomsOlder subjectsHamilton Depression Rating Scale scoresN-methyl-D-aspartate receptor antagonistSystematic reviewStudy participantsDepression Rating Scale scoresAdverse effectsBenefits of ketamineTolerability of ketamineCognitive adverse effectsCochrane Central RegisterTreatment-resistant depressionAnti-depressant effectsRelapse of symptoms
2020
A systematic review of ketamine for the treatment of depression among older adults
Gupta A, Dhar R, Patadia P, Funaro M, Bhattacharya G, Farheen SA, Tampi RR. A systematic review of ketamine for the treatment of depression among older adults. International Psychogeriatrics 2020, 33: 179-191. PMID: 32600480, DOI: 10.1017/s1041610220000903.Peer-Reviewed Educational MaterialsConceptsUse of ketaminePrimary outcome measureTreatment of depressionOlder adultsAdverse effectsOutcome measuresMontgomery-Asberg Depression Rating Scale scoreDepression Rating Scale scoresBenefits of ketamineCognitive adverse effectsRating Scale scoresEsketamine groupPlacebo groupRemission rateIntranasal ketamineKetamine administrationMADRS scoresInclusion criteriaDepressive symptomsCurrent evidenceScale scoreDepression symptomsKetamineSystematic reviewNegative trials